Investigational Drug Information for PTC299
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
What is the development status for investigational drug PTC299?
PTC299 is an investigational drug.
There have been 7 clinical trials for PTC299.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 9th 2020.
The most common disease conditions in clinical trials are Pneumonia, Sarcoma, Kaposi, and Central Nervous System Neoplasms. The leading clinical trial sponsors are PTC Therapeutics, United States Department of Defense, and National Cancer Institute (NCI).
There are nine US patents protecting this investigational drug and sixty international patents.
Summary for PTC299
| US Patents | 9 |
| International Patents | 60 |
| US Patent Applications | 45 |
| WIPO Patent Applications | 17 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2020-07-09) |
| Vendors | 14 |
Recent Clinical Trials for PTC299
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19) | PTC Therapeutics | Phase 2/Phase 3 |
| Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias | PTC Therapeutics | Phase 1 |
| PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for PTC299
Top disease conditions for PTC299
Top clinical trial sponsors for PTC299
US Patents for PTC299
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PTC299 | ⤷ Sign Up | Carboline derivatives useful in the inhibition of angiogenesis | PTC Therapeutics, Inc. (South Plainfield, NJ) | ⤷ Sign Up |
| PTC299 | ⤷ Sign Up | Carboline derivatives useful in the treatment of cancer | PTC Therapeutics, Inc. (South Planfield, NJ) | ⤷ Sign Up |
| PTC299 | ⤷ Sign Up | Administration of carboline derivatives useful in the treatment of cancer and other diseases | PTC Therapeutics, Inc. (South Plainfield, NJ) | ⤷ Sign Up |
| PTC299 | ⤷ Sign Up | Inhibition of VEGF translation | PTC Therapeutics, Inc. (South Plainfield, NJ) | ⤷ Sign Up |
| PTC299 | ⤷ Sign Up | Carboline derivatives useful in the inhibition of angiogenesis | PTC Therapeutics, Inc. (South Plainfield, NJ) | ⤷ Sign Up |
| PTC299 | ⤷ Sign Up | Carboline derivatives useful in the inhibition of angiogenesis | PTC Therapeutics, Inc. (South Plainfield, NJ) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PTC299
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PTC299 | Austria | AT547102 | 2024-03-15 | ⤷ Sign Up |
| PTC299 | Australia | AU2005222632 | 2024-03-15 | ⤷ Sign Up |
| PTC299 | Brazil | BRPI0508814 | 2024-03-15 | ⤷ Sign Up |
| PTC299 | Canada | CA2559408 | 2024-03-15 | ⤷ Sign Up |
| PTC299 | China | CN102408425 | 2024-03-15 | ⤷ Sign Up |
| PTC299 | China | CN1980672 | 2024-03-15 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
